ADAMANTANE RESEARCH / UPDATED 1 NOVEMBER 2026

Adamantane and related compounds

Experimental small molecules built around the adamantane cage, including Chlodantane, Cyclontane and coded ADK compounds tested in pharmacology studies.

Findings from selected studies

  • A Chlodantane analogue in mice

    After 14 days, treadmill performance in mice receiving the camphane analogue rose by 23.22–25.20%. Groups differed at baseline, and the treated animals approached control running times.

Browse study findings by subject ↓

Educational information only. Not medical advice. Seek qualified healthcare help for any medical condition. Animal experiments and patent claims do not establish safe personal use or protection from environmental hazards.

Chlodantane’s development history

New historical coverage traces the pharmacokinetic and toxicology record, Sirius University’s claim of clinical testing, and later publications including the 2025 gram-scale chemistry paper. Institutional statements and documented human-trial results are distinguished.

Read the Chlodantane history and source review ↗

Chemical classes and preparation differences

Bromantane is an arylamine. Chlodantane and ADK-918 are benzamides; Cyclontane is a hydroxyadamantane. The newer camphane candidates change the cage framework. “Successor” describes a research interest here, not demonstrated superiority or regulatory approval.

Neutral findings and study limitations

From ADK codes to modern cage analogues

  1. 1989 filing / 1996 publication: the original Chlodantane–ADK-918 certificate is now identified; its experimental tables still need recovery.
  2. 2016–2017 flexible Bromantane analogues: synthesis, pharmacology and basicity papers extend the arylamine branch. Parts II and IV remain bibliographic leads pending full review.
  3. 2018 phenoxyacetamides and 2019 cage-amine synthesis: distinct structural modifications, not interchangeable preparations.
  4. 2023 camphane benzamides and 2024 camphane anilines: separate animal research branches addressing endurance and behavior.

Modern paper-specific compound numbers are not historical ADK codes. ADK numbering does not establish the library’s size, discovery order or a continuous institutional program. No service-member trial has been verified here for Chlodantane or Cyclontane.

Compound and archival records

Some entries are well-identified experimental candidates; others are screening codes awaiting original structural records. The number of records is not a count of clinically effective drugs.

RecordIdentity and scopeSources
Chlodantane ↗N-(adamantan-2-yl)-4-chlorobenzamide (ADK-910), an experimental small molecule with an adamantane cage joined to a chlorobenzamide. Russian studies examined temperature stress and physical workload.

2019 · Patent ↗

2023 · Source record ↗

2019 · Source record ↗

Date unverified · Dissertation abstract transcription ↗

1996 · Dissertation abstract transcription ↗

1996 · Source record ↗

2018 · Source record ↗

2019 · Source record ↗

Date unverified · Source record ↗

Date unverified · Source record ↗

Date unverified · Source record ↗

Date unverified · Source record ↗

Date unverified · Source record ↗

Cyclontane ↗A synthetic adamantane derivative, also called ADK-638, studied on its own and in a formulation with sodium oxybate.

2018 · Patent ↗

2022 · Journal article; full-text reproduction ↗

2003 · Source record ↗

ADK-918 ↗The para-bromobenzamide counterpart of Chlodantane, N-(adamantan-2-yl)-4-bromobenzamide. It is chemically distinct from Bromantane.

2023 · Source record ↗

2019 · Source record ↗

Date unverified · Dissertation abstract transcription ↗

1996 · Dissertation abstract transcription ↗

1996 · Source record ↗

2018 · Source record ↗

ADK-957 ↗An experimental adamantane chlorophenoxyacetamide. A 2019 chemistry paper identifies the compound and cites earlier cold-exposure research without reporting the original results.

2019 · Source record ↗

ADK-963 ↗A historical research code for an ortho-hydroxyphenyl aminoadamantane described in an immunology dissertation. The available description does not resolve its stereochemistry.

Date unverified · Dissertation abstract transcription ↗

ADK-613 ↗A historical research code for the hydrochloride of an adamantyl-substituted para-fluoroaniline. The identification comes from a dissertation on immune regulation.

Date unverified · Dissertation abstract transcription ↗

Kemantane ↗A synthetic adamantane compound studied in Russian immune research, including historical clinical reports.

Date unverified · Dissertation abstract transcription ↗

Date unverified · Source record ↗

Date unverified · Source record ↗

Date unverified · Source record ↗

Date unverified · Source record ↗

Camphane chlorobenzamide ↗An experimental chlorobenzamide designed as a structural analogue of Chlodantane. It has a camphane cage in place of Chlodantane’s adamantane cage.

2023 · Source record ↗

2019 · Source record ↗

2019 · Source record ↗

Adamantylaminoethyl chlorophenoxyacetate ↗A synthetic adamantane-based ester described in Soviet patent SU1771186A1 for experimental temperature-stress research.

1995 · Source record ↗

ADK-559 ↗ADK-559 is an experimental N-substituted adamantylpiperazine. A historical screen reported weak inhibition of hepatic monooxygenases, enzymes involved in drug metabolism. The source does not identify the N-substituent.

1996 · Dissertation abstract transcription ↗

ADK-591 ↗ADK-591 is an experimental N-substituted adamantylpiperazine. A historical screen reported weak inhibition of hepatic monooxygenases, enzymes involved in drug metabolism. The source does not identify the N-substituent.

1996 · Dissertation abstract transcription ↗

ADK-676 ↗ADK-676 is an experimental N-substituted adamantylpiperazine. A historical screen reported weak inhibition of hepatic monooxygenases, enzymes involved in drug metabolism. The source does not identify the N-substituent.

1996 · Dissertation abstract transcription ↗

ADK-677 ↗ADK-677 is an experimental N-substituted adamantylpiperazine. A historical screen reported weak inhibition of hepatic monooxygenases, enzymes involved in drug metabolism. The source does not identify the N-substituent.

1996 · Dissertation abstract transcription ↗

ADK-790 ↗An experimental adamantane–benzimidazole compound studied for its effects on liver enzymes that metabolize drugs.

1996 · Dissertation abstract transcription ↗

ADK-828 ↗Adamantylidene-2,6-diacetonitrile, an experimental adamantane derivative. Animal studies examined induction of liver drug-metabolizing enzymes and anaphylactic reactions.

1996 · Dissertation abstract transcription ↗

ADK-829 ↗An experimental bromophenyl benzamide attached to an adamantane group, identified in a historical liver-enzyme screen.

1996 · Dissertation abstract transcription ↗

Camphane aniline 4e ↗A synthetic para-ethylphenyl camphane amine. Compound 4e is the designation used in a 2024 chemical study of structural analogues of Bromantane.

2024 · Source record ↗

What still needs recovery

The original RU2196575C2 Cyclontane experiments, the tables accompanying SU1646256A1, ADK-957’s original cold-exposure study, complete dissertation scans and independent safety/clinical research remain priorities. Shared filing dates or investigators do not by themselves prove a single coordinated development program.

View the Cyclontane combination in the research matrix ↗

Bibliography and source appraisal

2019Patent / reported experimentsFull text available

Chlorobenzoylaminoadamantane formulation for physical performance at high and low temperatures

Format: Patent · Reviewed: Selected animal experiments and formulation description reviewed

· RU2704126C2; filed 28 November 2016

The patent reports longer treadmill endurance with the Chlodantane formulation under heat and cold. In heat, the selected comparison was 56.23 ± 5.36 versus 27.69 ± 1.31 minutes in controls. Ladasten showed a heat signal at the higher tested exposure but no significant cold-endurance benefit.

Results and tables

Reported patent results

Reported findings

The formulation increased rod-retention time after cold stress but did not restore the intact-animal value.

Animal experiments on a Chlodantane formulation under temperature stress; the cited result below is from the cold-exposure rotating-rod experiment.

Population or model Male mice; treadmill tests at +40°C and −5°C

Results · Description: final hypothermia/Rotarod experiment and narrative accompanying Table 5.
MeasureResultComparison, timing and statistics
Cold-exposure motor coordination24.0 (17.0–33.0) s with the formulation versus 11.5 (9.5–15.5) s in cold-exposed controlsMedians and quartiles; intact animals 127.0 (100.5–183.0) s · p=0.04 versus cold control
Sydnocarb comparator6.5 (5.0–9.0) s versus 11.5 (9.5–15.5) s cold controlWorse retention in this test; not general clinical inferiority · p=0.04

These findings concern a specific formulation and mouse model. They do not establish human occupational performance or protection under dangerous temperature exposure.

Source for these results ↗ · Reviewed 2026-11-06

Population / setting
Male mice; treadmill tests at +40°C and −5°C
Source reviewed
Selected source passages checked; complete methods and risk of bias not appraised.
Study limitations
  • Patent-reported animal results are not an independently replicated clinical trial or evidence of safe heat/cold exposure.
  • The response was non-linear; formulation-specific effects cannot be assigned to every Chlodantane product.
  • The groups were small, and the source gives conflicting comparison-group sizes.

Reviewed 2026-10-03.

Read the source ↗
2018Patent / reported experimentsFull text available

Cyclontane and sodium oxybate pharmaceutical composition for desynchronosis

Format: Patent · Reviewed: Selected methods and sleep-result passages reviewed

· RU2674342C2; filed 28 November 2016; Russian Federation represented by Ministry of Defense

The combination was investigated for activity rhythms, performance, operant learning and EEG sleep. REM duration exceeded the untreated desynchronosis group, but REM latency remained prolonged relative to baseline: recovery was incomplete.

Results and tables

Reported patent results

Reported findings

Some activity and REM-sleep measures improved relative to untreated desynchronization, while sleep timing remained abnormal.

Desynchronized rats and mouse safety observations for Cyclontane plus sodium oxybate; no human jet-lag trial.

Population or model Rodent circadian-disruption experiments; 18-hour light/dark schedule

Results · Description: wheel-running results, sleep-wake narratives around Tables 2–3 and 14-day observation.
MeasureResultComparison, timing and statistics
Wheel activityApproximately 700 revolutions with the combination versus 200 with saline; baseline about 900Desynchronized rats · Third day
REM-sleep durationReported 1.7-fold longer than untreated desynchronization; 62.5% versus 30% exceeded the stated REM thresholdThreshold: REM duration >50% of the baseline group average
Persisting abnormalityREM-onset latency remained approximately twice baseline; wakefulness remained elevatedImprovement versus injury did not mean normalization
Acute observationsNo deaths or listed overt neurological/behavioral abnormalities reportedAnimal observations only · 14 days

The combination does not isolate Cyclontane, and sleep comparisons vary by experiment. Animal safety observations do not establish human safety of this combination.

Source for these results ↗ · Reviewed 2026-11-06

Population / setting
Rodent circadian-disruption experiments; 18-hour light/dark schedule
Source reviewed
Selected source passages checked; complete methods and risk of bias not appraised.
Study limitations
  • Combination findings cannot establish Cyclontane’s independent effect; patent evidence does not establish human efficacy or safety.
  • No clinical sleep benefit or safe self-use regimen follows from these experiments.

Reviewed 2026-10-03.

Read the source ↗
2022Animal / experimentalFull text available

Comparative study of the effects of adamantane derivatives on the behavior of CD-1 mice with different phenotype of attention stability

Format: Journal article; full-text reproduction · Reviewed: Abstract, identity passage and selected methods reviewed

N. A. Sukhorukova, R. M. Salimov, G. I. Kovalev · Pharmacokinetics and Pharmacodynamics. 2022;(1):3–8

Cyclantane, Ladasten and memantine partially restored attention in the low-attention subgroup, but worsened attention in the initially high-attention subgroup by 40–47% relative to controls. Exploratory and locomotor measures did not change in parallel.

Population / setting
CD-1 mice separated by baseline attention phenotype; three administrations
Source reviewed
Selected source passages checked; complete methods and risk of bias not appraised.
Study limitations
  • Phenotype-dependent mouse behavior is not evidence for human ADHD treatment or general cognitive enhancement.
  • Dose, route and repeated-testing effects limit extrapolation; the names Cyclantane and Cyclontane refer here to ADK-638.

Reviewed 2026-10-03.

Read the source ↗
2023Animal / experimentalFull text available

Comparative Evaluation of the Pharmacological Activity of Fatty Aromatic Amides and Amines with a Framework Moiety and Their Non-Covalent Complexes

A. A. Vernigora, R. V. Brunilin, O. V. Vostrikova, et al. · Pharmaceutical Chemistry Journal. 57(4):523–534

The camphane chlorobenzamide candidate increased treadmill performance by 23.22–25.20% after 14 days of administration. Baseline group differences complicate interpretation; the text describes convergence toward control running times. Complexation of Chlodantane, Bromantane and ADK-918 neutralized their actoprotective effects in the tested preparations; the new derivatives were classified as moderately toxic.

Population / setting
Mouse pharmacology experiments
Source reviewed
Institute abstract and selected author-uploaded full-text passages checked, including the 7/14-day schedule and baseline-imbalance discussion; complete tables not independently appraised.
Study limitations
  • Abstract-level animal findings do not establish human performance benefits or improved clinical safety.
  • An effect at a 14-day assessment does not prove a benefit persisted for 14 days after one dose.
  • The Russian and English versions are one publication, not independent replication.

Reviewed 2026-10-03.

Read the source ↗
2019Analytical / composition studyFull text available

Synthesis of New Camphane-Type Amides: Potential Synthetic Adaptogenes

I. A. Novakov, R. V. Brunilin, G. M. Butov, A. A. Vernigora, M. B. Navrotskii, A. S. Yablokov, S. N. Voloboev · Russian Journal of General Chemistry. 89(3):399–404

The study reports synthesis and characterization of camphane analogues and links their design to Chlodantane and related adamantanes. ADK-957 appears as a chlorophenoxyacetamide background lead; cited cold-protection activity is not a new clinical result in this chemistry paper.

Population / setting
Chemical synthesis and characterization; background pharmacology citations
Source reviewed
Author-uploaded paper’s accessible chemistry/background passages checked; earlier pharmacology not independently recovered.
Study limitations
  • Chemical characterization and a potential-adaptogen label do not demonstrate pharmacological efficacy.
  • ADK-957’s original cold-exposure experiment and detailed safety data remain acquisition targets.

Reviewed 2026-10-03.

Read the source ↗
Year unconfirmedAnimal / experimentalRussian-language source

Role of neurotropic adamantane-containing compounds in the regulation of immunity

· Dissertation; OCR reproduction

Format: Dissertation abstract transcription · Reviewed: See scope

· Dissertation author’s abstract; third-party Russian transcription

The program reports preparation-dependent antibody-forming-cell, T-cell and post-irradiation colony responses. ADK-910 showed a strong humoral response without increasing the delayed-hypersensitivity endpoint; immune stimulation was not uniform across assays.

Population / setting
Multiple mouse strains and laboratory immune assays
Source reviewed
Selected source passages checked; complete methods and risk of bias not appraised.
Study limitations
  • OCR transcription requires comparison with the original; author/date and full tables are not entered as verified metadata.
  • Immune and colony assays do not demonstrate better health, infection prevention or long-term stem-cell expansion in people.

Reviewed 2026-10-03.

Read the source ↗
1996Animal / experimentalRussian-language source

Influence of hereditary and environmental factors on cytochrome P450 metabolic activity and drug effects

· Dissertation; OCR reproduction

Format: Dissertation abstract transcription · Reviewed: See scope

T. G. Khlopushina · Doctoral dissertation author’s abstract. Moscow, 1996

ADK-559/591/676/677 weakly inhibited hepatic monooxygenases; ADK-709/790/828/829/910/918 induced P450. The author also reports fewer anaphylaxis deaths with ADK-828 and ADK-829 in guinea pigs. Different controls and OCR table ambiguities prevent a reliable cross-compound ranking.

Population / setting
Mouse hepatic-enzyme screening and sensitized guinea-pig anaphylaxis experiments
Source reviewed
Selected source passages checked; complete methods and risk of bias not appraised.
Study limitations
  • Original structures and tables require checking against the scan; transcription errors are possible.
  • Enzyme induction does not establish detoxification benefits or predict safe human drug combinations.
  • Animal anaphylaxis results are not evidence for treating allergy in people; proposed adjunct uses were development suggestions.

Reviewed 2026-10-03.

Read the source ↗
1995Patent / reported experimentsFull text available

Para-chlorophenoxyacetic acid adamant-2-ylaminoethyl ester hydrochloride with claimed thermoprotective and psychostimulant activities

N. V. Klimova, T. D. Karpova, Sh. Karadzhaev, N. P. Bykov, N. I. Avdyunina, B. M. Pyatin, I. S. Morozov, G. V. Pushkar, I. M. Zinovyeva · SU1771186A1; filed 23 October 1990; published 10 November 1995

The patent identifies a distinct aminoethyl ester and claims thermoprotective and psychostimulant activity. It is not ADK-957’s amide and is not Chlodantane.

Results and tables

Reported patent results

Experimental results unavailable in the source

No experimental result can be responsibly transcribed from the accessed entry.

The accessed Google Patents entry supplies bibliographic identity for the thermoprotective ester but no readable experiment section.

Population or model Patent-described experimental compound

Results · Accessed original-publication index entry; original experimental text not available.
MeasureResultComparison, timing and statistics
Thermoprotection or stimulation outcomeNo extractable measured value in the accessed recordClaimed properties are not substituted for observed results

The original scan is needed. No effect size, group size, exposure or clinical benefit is inferred from the title.

Source for these results ↗ · Reviewed 2026-11-06

Population / setting
Patent-described experimental compound
Source reviewed
Patent identity, title, inventors and dates checked; quantitative pharmacology not appraised.
Study limitations
  • Patent claims are not verified clinical findings; experimental magnitude and independent replication remain unassessed.

Reviewed 2026-10-03.

Read the source ↗
2003Patent / reported experimentsBibliographic record

Original Cyclontane / ADK-638 patent trail

· RU2196575C2; cited in later RU2674342C2

The later patent cites this earlier Cyclontane development record. Original behavioral and toxicity comparisons require direct verification before numerical claims are reproduced.

Results and tables

Reported patent results

Findings described in words

The patent reports increased running-to-exhaustion performance and stimulant-related behavioral effects.

Original Cyclontane/ADK-638 animal pharmacology, including treadmill groups of 8 preselected rats.

Population or model Original experiments not independently recovered for this entry

Results · Treadmill and anti-catalepsy experiments, Tables 5–6 narrative.
MeasureResultComparison, timing and statistics
Treadmill performanceSignificantly longer running-to-exhaustion at selected tested exposures8 rats per group; exact table means not transcribed
Behavioral pharmacologyAnti-cataleptic activity and stimulant-like responses describedModel-specific comparisons do not establish human superiority to Bromantane

Preselected animal performance is not a human occupational outcome, and the patent’s clinical recommendations exceed the experiments. Findings belong to ADK-638 rather than every related cage compound.

Source for these results ↗ · Reviewed 2026-11-06

Population / setting
Original experiments not independently recovered for this entry
Source reviewed
Prior-art citation followed from the 2018 patent; original retrieval unsuccessful.
Study limitations
  • Bibliographic lead only; neither potency ratios nor toxicity estimates from secondary accounts are treated as verified here.

Reviewed 2026-10-03.

Read the source ↗
1996Patent / reported experimentsEnglish abstract

Original Chlodantane and ADK-918 certificate: environmental resistance and immunostimulation

· SU1646256A1

The abstract claims protection during overheating, hypobaric hypoxia and water deprivation, and improved rat operant activity under fatigue. Filing dates to 13 July 1989; publication was 10 June 1996.

Results and tables

Reported patent results

Experimental results unavailable in the source

Experimental results could not be extracted from the accessed source; the later Chlodantane formulation patent is a separate disclosure.

The accessed Google Patents entry supplies bibliographic identity but no readable experimental description.

Population or model Preclinical research; no human efficacy established

Results · Accessed original-publication index entry; description and result tables unavailable.
MeasureResultComparison, timing and statistics
Original experimental outcomesNot available in the accessed bibliographic entryNo animal survival percentage or human performance effect is invented

The original certificate is unavailable. Whether it contains experimental results remains unknown.

Source for these results ↗ · Reviewed 2026-11-06

Population / setting
Preclinical research; no human efficacy established
Source reviewed
Source identity and selected abstract or text passages checked; complete methods not appraised.
Study limitations
  • Only the patent abstract and metadata were recovered; the two experimental tables remain unavailable.
  • Abstract toxicity figures lack adequate species/route context here and are not used to rank safety.

Reviewed 2026-10-03.

Read the source ↗
2018Patent / reported experimentsFull text available

Phenoxyacetamide structural analogues of Chlodantane and ADK-918

· RU2660654C1; Volgograd State Technical University

The patent explicitly identifies its two adamantane-containing phenoxyacetamides as structural analogues of ADK-910 and ADK-918. This documents a later medicinal-chemistry branch, not demonstrated clinical superiority.

Results and tables

Reported patent results

Reported findings

The disclosure reports synthesis yields; it does not supply a verified clinical adaptogenic result.

Chemical preparation and characterization of two new phenoxyacetamide analogues, with the original ADK compounds used as structural context.

Population or model Preclinical research; no human efficacy established

Results · Final two chemical examples and characterization results.
MeasureResultComparison, timing and statistics
Analogue 1 recovery15.1 g, 85% yieldManufacturing result for the newly claimed analogue, not Chlodantane or ADK-918
Analogue 2 recovery80% yield; melting interval 94.5–95.0°CA different new analogue; analytical characterization

Chemical yields do not establish biological adaptogenic activity. The claimed compounds are structural analogues of the reference candidates, not the candidates themselves.

Source for these results ↗ · Reviewed 2026-11-06

Population / setting
Preclinical research; no human efficacy established
Source reviewed
Source identity and selected abstract or text passages checked; complete methods not appraised.
Study limitations
  • Chemistry and preclinical observations do not establish human efficacy or safety.

Reviewed 2026-10-03.

Read the source ↗
2016Analytical / composition studyEnglish abstract

Potential synthetic adaptogens I: new N-[(adamantan-1-yl)methyl]aniline derivatives

· Russian Chemical Bulletin. 65:1336–1340

The authors prepared more conformationally flexible Bromantane analogues and studied how reaction conditions affected products and yields.

Population / setting
Preclinical research; no human efficacy established
Source reviewed
Source identity and selected abstract or text passages checked; complete methods not appraised.
Study limitations
  • Chemistry and preclinical observations do not establish human efficacy or safety.

Reviewed 2026-10-03.

Read the source ↗
2017Study design unresolvedBibliographic record

Potential Synthetic Adaptogens II: synthesis and pharmacological activity of conformationally labile Bromantane analogues

· Pharmaceutical Chemistry Journal. 50:781–787

Bibliographic record for the N-[(adamantan-1-yl)methyl]-4-bromoaniline series. Compound-specific pharmacological results await full-text appraisal.

Population / setting
Preclinical research; no human efficacy established
Source reviewed
Source identity and selected abstract or text passages checked; complete methods not appraised.
Study limitations
  • Chemistry and preclinical observations do not establish human efficacy or safety.

Reviewed 2026-10-03.

Read the source ↗
2017Analytical / composition studyBibliographic record

Potential Synthetic Adaptogens IV: synthesis and study of basicity of new N-[(adamantan-1-yl)methyl]aniline derivatives

· Russian Journal of Organic Chemistry. 53(5):663–672

Publisher contents identify the basicity study. Brain penetration and clinical activity cannot be inferred from basicity measurements.

Population / setting
Preclinical research; no human efficacy established
Source reviewed
Source identity and selected abstract or text passages checked; complete methods not appraised.
Study limitations
  • Chemistry and preclinical observations do not establish human efficacy or safety.

Reviewed 2026-10-03.

Read the source ↗
2019Analytical / composition studyRussian-language source

Potential Synthetic Adaptogens V: synthesis of cage monoamines by the Schwenk–Papa reaction

· Zhurnal Organicheskoi Khimii. 55(11):1781–1788

Camphor oximes yielded cage amines; norcamphor and adamantanone oximes also produced alcohol by-products. These intermediates support camphane/norcamphane replacements for adamantane scaffolds. This is synthesis research, not an efficacy trial.

Population / setting
Preclinical research; no human efficacy established
Source reviewed
Source identity and selected abstract or text passages checked; complete methods not appraised.
Study limitations
  • Chemistry and preclinical observations do not establish human efficacy or safety.

Reviewed 2026-10-03.

Read the source ↗
2024Animal / experimentalRussian-language source

Psychotropic activity of N-(camphan-2-yl)anilines: new structural analogues of Bromantane

· Pharmacy & Pharmacology. 12(4):295–308

The Russian abstract identifies para-ethylphenyl compound 4e as a lead with anxiolytic-like activity and signals in novel-object recognition and extrapolation-escape tests in rodents.

Population / setting
Preclinical research; no human efficacy established
Source reviewed
Source identity and selected abstract or text passages checked; complete methods not appraised.
Study limitations
  • Russian abstract and bibliography checked, not the complete experimental tables.
  • This record follows the Russian 4e designation; the compound numbers in the two languages still need to be checked against the chemical structures. No human benefit or superiority is established.

Reviewed 2026-10-03.

Read the source ↗

Complete bibliography ↗

Study findings by subject

20 source records

2023 · Lab research

Structure-Based Design, Synthesis, and Biological Evaluation of the Cage–Amide Derived Orthopox Virus Replication Inhibitors

The paper reports antiviral activity for a family of cage-amides in cell culture. Its lead compound 18a had a reported selectivity index of 18,214 against vaccinia. This is a distinct experimental compound, not a numerical clinical result for Chlodantane. Modelling suggested p37 as a possible target; the paper did not demonstrate direct target binding.

Methods and source ↗ · Chlodantane · Bromantane

2025 · Laboratory analysis

A sustainable twist on the Ritter reaction: iron-based deep eutectic solvents as a green route to amide synthesis

The publication uses Chlodantane as a gram-scale demonstration of a reusable reaction medium for amide chemistry. It reports an 89% isolated yield for that demonstration and evaluates process sustainability. Its significance is continued chemical-method development and analytical characterization, rather than evidence of clinical effectiveness.

Methods and source ↗ · Chlodantane

2023 · Animal research

Comparative Evaluation of the Pharmacological Activity of Fatty Aromatic Amides and Amines with a Framework Moiety and Their Non-Covalent Complexes

The camphane chlorobenzamide candidate increased treadmill performance by 23.22–25.20% after 14 days of administration. Baseline group differences complicate interpretation; the text describes convergence toward control running times. Complexation of Chlodantane, Bromantane and ADK-918 neutralized their actoprotective effects in the tested preparations; the new derivatives were classified as moderately toxic.

Methods and source ↗ · Chlodantane · Bromantane · ADK-918 · Camphane chlorobenzamide

1996 · Animal research

Influence of hereditary and environmental factors on cytochrome P450 metabolic activity and drug effects

ADK-559/591/676/677 weakly inhibited hepatic monooxygenases; ADK-709/790/828/829/910/918 induced P450. The author also reports fewer anaphylaxis deaths with ADK-828 and ADK-829 in guinea pigs. Different controls and OCR table ambiguities prevent a reliable cross-compound ranking.

Methods and source ↗ · Bromantane · Chlodantane · ADK-918 · ADK-559 · ADK-591 · ADK-676 · ADK-677 · ADK-790 · ADK-828 · ADK-829